Singapore - English - HSA (Health Sciences Authority)

astrazeneca singapore pte ltd - budesonide - powder, metered - 200 mcg/dose - budesonide 200 mcg/dose

New Zealand - English - Medsafe (Medicines Safety Authority)

astrazeneca limited - terbutaline sulfate 0.5mg - powder for inhalation - 0.5 mg/dose - active: terbutaline sulfate 0.5mg

Singapore - English - HSA (Health Sciences Authority)

astrazeneca singapore pte ltd - ticagrelor - tablet, film coated - 90 mg - ticagrelor 90 mg

Australia - English - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - goserelin, quantity: 3.6 mg - implant - excipient ingredients: polyglactin - prostate cancer: palliative treatment of metastatic or locally advanced prostate cancer, where suitable for hormonal manipulation. adjuvant and neo-adjuvant therapy in combination with radiotherapy for the management of locally advanced prostate cancer in men suitable for hormonal manipulation. breast cancer: treatment of advanced breast cancer (t3b, t4 or any t with n2, 3 or m plus) in premenopausal women suitable for hormonal manipulation. adjuvant therapy in early breast cancer, in pre- and perimenopausal women suitable for hormonal manipulation. endometriosis: in the management of visually proven endometriosis to reduce symptoms including pain and the size and number of endometrial lesions. uterine fibroids: in the management of fibroids, astrazeneca goserelin shrinks the lesions and reduces the symptoms, including pain. astrazeneca goserelin also increases the haemoglobin concentration and haematocrit in women with anaemia attributable to menorrhagia. it is used as an adjunct to surgery to facilitate the operative technique and reduce operativeblood loss. endometrial thinning: use as an endometrial thinning agent prior to endometrial ablation. assisted reproduction: pituitary down regulation in preparation for controlled ovarian superstimulation.

European Union - English - EMA (European Medicines Agency)

astrazeneca ab - gefitinib - carcinoma, non-small-cell lung - antineoplastic agents - iressa is indicated for the treatment of adult patients with locally advanced or metastatic non-small-cell lung cancer with activating mutations of epidermal-growth-factor-receptor tyrosine kinase.

European Union - English - EMA (European Medicines Agency)

astrazeneca ab - roflumilast - pulmonary disease, chronic obstructive - drugs for obstructive airway diseases, - daliresp is indicated for maintenance treatment of severe chronic obstructive pulmonary disease (copd) (fev1 post-bronchodilator less than 50% predicted) associated with chronic bronchitis in adult patients with a history of frequent exacerbations as add-on to bronchodilator treatment.

European Union - English - EMA (European Medicines Agency)

astrazeneca ab - roflumilast - pulmonary disease, chronic obstructive - drugs for obstructive airway diseases, - libertek is indicated for maintenance treatment of severe chronic obstructive pulmonary disease (copd) (fev1 post-bronchodilator less than 50% predicted) associated with chronic bronchitis in adult patients with a history of frequent exacerbations as add-on to bronchodilator treatment.

Ireland - English - HPRA (Health Products Regulatory Authority)

astrazeneca ab - esomeprazole - powder for solution for injection/infusion - 40 milligram(s) - proton pump inhibitors; esomeprazole

Ireland - English - HPRA (Health Products Regulatory Authority)

astrazeneca ab - esomeprazole - gastro-resistant tablet - 20 milligram(s) - proton pump inhibitors; esomeprazole

Ireland - English - HPRA (Health Products Regulatory Authority)

astrazeneca ab - esomeprazole - gastro-resistant tablet - 40 milligram(s) - proton pump inhibitors; esomeprazole